Fascin-1 Protein: A Key Player in Cervical Cancer Spread and Treatment Resistance
New research identifies Fascin-1 as a key driver of cervical cancer progression, metastasis, and treatment resistance, offering promising targets for future therapies.
Cervical cancer remains a significant health challenge worldwide, ranking as the fourth most common cancer among women. The primary cause is persistent infection with high-risk human papillomavirus (HPV) strains, particularly HPV16 and HPV18. Despite advancements in treatment modalities such as surgery, radiation therapy, and chemotherapy, patients with advanced or metastatic disease often face limited options and poor prognoses.
Recent research conducted by scientists at The Fourth Hospital of Shijiazhuang has uncovered the critical role of a protein called Fascin-1 in the progression of cervical cancer. Normally, Fascin-1 is expressed at low levels in healthy cervical tissue, but it becomes significantly elevated in cancerous tissues. This rise in Fascin-1 levels correlates strongly with more aggressive disease and worse survival outcomes.
The study, published in the journal Biomolecules and Biomedicine, utilized patient tissue analysis, cell-based experiments, and animal models to explore Fascin-1's functions. Findings revealed that Fascin-1 promotes tumor cell proliferation, migration, and invasion, primarily by activating the Wnt/β-catenin signaling pathway—a pathway well known for its involvement in cancer development.
Importantly, silencing or inhibiting Fascin-1 resulted in decreased tumor growth and metastasis in models and increased cancer cell sensitivity to the chemotherapy drug cisplatin. These results suggest that Fascin-1 serves both as a biomarker for aggressive cervical cancer and as a promising therapeutic target.
Although specific drugs to inhibit Fascin-1 are not yet approved for clinical use, ongoing trials are testing candidates like NP-G2-044/DC05F01 for other solid tumors. This opens up the potential for future treatments targeting Fascin-1 in cervical cancer patients.
Overall, this research enhances understanding of the molecular mechanisms driving cervical cancer spread and resistance to therapy. Targeting Fascin-1 could pave the way for more effective diagnostic and treatment strategies, ultimately improving patient outcomes.
Source: [https://medicalxpress.com/news/2025-09-fascin-protein-driver-cervical-cancer.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding the Differences Between Sperm and Semen: Can Pre-Ejaculate Lead to Pregnancy?
Learn about the key differences between sperm and semen, the role of pre-ejaculate, and how these factors influence male fertility and pregnancy risks.
Enhanced Access but Delayed Treatment in Telestroke Patient Care: Insights from a Michigan Study
A Michigan-led study reveals that while telestroke evaluations increase treatment chances, they also introduce significant delays, emphasizing the need for process improvements to ensure timely stroke care.
How Historical Redlining Increases Breast Cancer Risks and Impacts Survival
New research links historic redlining policies to increased breast cancer risks and lower survival rates in affected U.S. neighborhoods, highlighting ongoing health disparities rooted in racial and socioeconomic segregation.
GSK Acquires Promising Liver Disease Medication in Deal Valued at Up to $2 Billion
GSK is investing up to $2 billion to acquire efimosfermin, a promising drug in late-stage trials for treating fatty liver disease, which could revolutionize care and lower healthcare costs. Source: medicalxpress.com